TruScreen is the only advanced technology in the world that uses "standardized" histologic results to identify cervical cancer. This is a new non-invasive technique, giving results in place only after 3-5 minutes of implementation. A solution that helps the female community to access the Cervical Cancer prevention and control program effectively.
TruSceen has been clinically tested by over 10,000 women arround the world

TruSceen has been clinically tested by over 10,000 women arround the world

TruSceen has been clinically tested by over 10,000 women arround the world

TruScreen's clinical efficacy has been shown to be consistent over many years in clinical studies conducted in many countries. TruScreen supplies instant results, non-sampled, less pain, minimizing invasive behavior, and is popular with women around the w

View Details...
Reduce the burden of disease through screening.

Reduce the burden of disease through screening.

Reduce the burden of disease through screening.

The sooner you find out, the better chance of preventing it. Regular checkups and screenings help to detect abnormalities that are directly related to the development of cancer in the future.

View Details...
Cervical Cancer is main cause of death in the world

Cervical Cancer is main cause of death in the world

Cervical Cancer is main cause of death in the world

Cancer of the cervix is a preventable disease, but it causes very high rates of cancer among women.In the world, more than 500,000 new cases of cervical cancer are detected and more than 270,000 people die from the disease each year.

View Details...
Cervical cancer screening in the world

Cervical cancer screening in the world

Cervical cancer screening in the world

Millions of women worldwide unable to access cervical cancer prevention and screening. When the disease is discovered, it is too late for treatment.

View Details...
Cancer screening plan (2016-2025) of Vietnam

Cancer screening plan (2016-2025) of Vietnam

Cancer screening plan (2016-2025) of Vietnam

In 2010, there were 5,664 women diagnosed with cervical cancer. The standardized incidence of cervical cancer (ASR) was 13.6 per 100,000 women. This rate is lower than that in Southeast Asia (15.8 per 100,000). This rate is tending to increase, especially

View Details...
Millions of women worldwide are unable to access cervical cancer screening.

Millions of women worldwide are unable to access cervical cancer screening.

Millions of women worldwide are unable to access cervical cancer screening.

Pap smear tests are ineffective in low-resource or developing health economies due to a lack of infrastructure, highly trained personnel required to read the smear and delays in reporting results, particularly in remote locations. Each year more than 270,

View Details...

TruScreen has been successfully used by more than 10,000 patients from 17 standard medical facilities in various countries such as Australia, UK, Canada, Russia , China, South Korea, Mexico, Italy, Latin America, etc. .. confirm TruScreen sensitivity for low-grade lesions of 75% and high lesions of 90% and medium for all lesions is 86%.
Back to top